These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23405108)

  • 1. Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent.
    Bagchi DP; Yu L; Perlmutter JS; Xu J; Mach RH; Tu Z; Kotzbauer PT
    PLoS One; 2013; 8(2):e55031. PubMed ID: 23405108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a Putative α-synuclein Radioligand Using an in silico Similarity Search.
    Janssen B; Tian G; Lengyel-Zhand Z; Hsieh CJ; Lougee MG; Riad A; Xu K; Hou C; Weng CC; Lopresti BJ; Kim HJ; Pagar VV; Ferrie JJ; Garcia BA; Mathis CA; Luk K; Petersson EJ; Mach RH
    Mol Imaging Biol; 2023 Aug; 25(4):704-719. PubMed ID: 36991273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Silico, in Vitro, and in Vivo Evaluation of New Candidates for α-Synuclein PET Imaging.
    Verdurand M; Levigoureux E; Zeinyeh W; Berthier L; Mendjel-Herda M; Cadarossanesaib F; Bouillot C; Iecker T; Terreux R; Lancelot S; Chauveau F; Billard T; Zimmer L
    Mol Pharm; 2018 Aug; 15(8):3153-3166. PubMed ID: 29989823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha Synuclein Fibrils Contain Multiple Binding Sites for Small Molecules.
    Hsieh CJ; Ferrie JJ; Xu K; Lee I; Graham TJA; Tu Z; Yu J; Dhavale D; Kotzbauer P; Petersson EJ; Mach RH
    ACS Chem Neurosci; 2018 Nov; 9(11):2521-2527. PubMed ID: 29750499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
    Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
    Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic Insight into the Binding Profile of DCVJ and α-Synuclein Fibril Revealed by Multiscale Simulations.
    Kuang G; Murugan NA; Ågren H
    ACS Chem Neurosci; 2019 Jan; 10(1):610-617. PubMed ID: 30277753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligodendrocytes Prune Axons Containing α-Synuclein Aggregates In Vivo: Lewy Neurites as Precursors of Glial Cytoplasmic Inclusions in Multiple System Atrophy?
    De Nuccio F; Kashyrina M; Serinelli F; Laferrière F; Lofrumento DD; De Giorgi F; Ichas F
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains.
    Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A
    Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model.
    Behere A; Thörnqvist PO; Winberg S; Ingelsson M; Bergström J; Ekmark-Lewén S
    J Neurosci Res; 2021 Oct; 99(10):2525-2539. PubMed ID: 34292621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein modulates tau spreading in mouse brains.
    Bassil F; Meymand ES; Brown HJ; Xu H; Cox TO; Pattabhiraman S; Maghames CM; Wu Q; Zhang B; Trojanowski JQ; Lee VM
    J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33091110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of protein interfaces between α-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p.
    Redeker V; Pemberton S; Bienvenut W; Bousset L; Melki R
    J Biol Chem; 2012 Sep; 287(39):32630-9. PubMed ID: 22843682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structurally distinct α-synuclein fibrils induce robust parkinsonian pathology.
    Hayakawa H; Nakatani R; Ikenaka K; Aguirre C; Choong CJ; Tsuda H; Nagano S; Koike M; Ikeuchi T; Hasegawa M; Papa SM; Nagai Y; Mochizuki H; Baba K
    Mov Disord; 2020 Feb; 35(2):256-267. PubMed ID: 31643109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
    Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
    Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
    McGlinchey RP; Lacy SM; Huffer KE; Tayebi N; Sidransky E; Lee JC
    J Biol Chem; 2019 Jun; 294(25):9973-9984. PubMed ID: 31092553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
    Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of α-Synuclein Seeding-Dependent Aggregation by ssDNA Aptamers Specific to C-Terminally Truncated α-Synuclein Fibrils.
    Hmila I; Sudhakaran IP; Ghanem SS; Vaikath NN; Poggiolini I; Abdesselem H; El-Agnaf OMA
    ACS Chem Neurosci; 2022 Dec; 13(23):3330-3341. PubMed ID: 36348612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease.
    Fares MB; Maco B; Oueslati A; Rockenstein E; Ninkina N; Buchman VL; Masliah E; Lashuel HA
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E912-21. PubMed ID: 26839406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.